Although there are currently no clinically approved agents targeting VCAM-1, Natalizumab, an agent that targets α4β1 and effectively blocks VCAM-1-α4β1 interaction, has become one of the most effective therapies for multiple sclerosis [51]. This evidence concerns the gene VCAM1 and multiple sclerosis.